The Zhitong Finance App learned that Corning Jerry Pharmaceutical-B (09966) rose by nearly 9%. As of press release, it had risen 8.34% to HK$9.16, with a turnover of HK$14.212,200.

According to the news, Corning Jerry Pharmaceuticals previously announced that the company will hold a board meeting on August 27, 2026 (Thursday) to consider and approve the interim results of the company and its subsidiaries for the six months ended June 30, 2026, and to deal with other matters.

Notably, on August 4, Corning Jerry announced that the company reached an overseas license agreement with PathosAI of the United States for the self-developed TROP2/HER3 ADC JSKN016, and its core assets went overseas. Dongwu Securities pointed out that the partner Pathos is an AI-driven precision oncology research and development company with strong capital and rising valuation. The potential value-added space of this exchange, which includes preferred stock subscription warrants, is worth paying attention to.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.